Emerging data reveals significant synergy when combining antibody-drug conjugates (ADCs) like polatuzumab vedotin with bispecific antibodies like glofitumab. These combinations show impressive results in relapsed/refractory non-Hodgkin lymphoma, signaling a major future direction for developing more potent therapies.
As CAR-T cell therapies are increasingly adopted for second-line treatment of large cell lymphoma, epcoritamab is solidifying its role as a critical, potentially curative replacement option in the third-line setting. This establishes a clear sequential treatment pathway for patients who continue to relapse.
Long-term follow-up from the Epcor-NHL1 trial reveals that epcoritamab monotherapy can produce highly durable complete responses in relapsed/refractory large B-cell lymphoma. With some patients remaining in remission for over 54 months, the therapy is positioned as a potential curative option in this setting.